

## DECLARATION

As below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below next to our names.

The below named inventors are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled **NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENTS**, the specification of which was filed as PCT International Application No. PCT/EP95/04155 on October 23, 1995 and was not amended under PCT Article 19.

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims.

We acknowledge the duty to disclose to the Patent and Trademark Office all information known to us to be material to patentability of the subject matter claimed in this application, as "materiality" is defined in Title 37, Code of Federal Regulations, § 1.56.

We hereby claim foreign priority benefits under Title 35, United States Code, § 119 (a)-(d) of any foreign application(s) for patent listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

<u>PRIOR FOREIGN APPLICATION(S)</u>			<u>Priority Claimed</u>
<u>95870076.7</u>	<u>Europe</u>	<u>28 June 1995</u>	<u>Yes</u>
(Number)	(Country)	(Date Filed)	
<u>94870166.9</u>	<u>Europe</u>	<u>21 October 1994</u>	<u>Yes</u>
(Number)	(Country)	(Date Filed)	

We hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, we acknowledge the duty to disclose all information known to me to be material to patentability of the subject matter claimed in this application, as "materiality" is defined in Title 37, Code of Federal Regulations, § 1.56, which become available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/EP95/04155</u>	<u>October 23, 1995</u>
(International Application No.)	(International Filing Date)


We hereby direct that all correspondence and telephone calls be addressed to:

Patricia A. Kammerer  
Arnold, White & Durkee  
P.O. Box 4433  
Houston, Texas 77210-4433  
(713) 787-1438



attorneys for the prospective assignee of this application.

WE HEREBY DECLARE THAT ALL STATEMENTS MADE OF OUR OWN KNOWLEDGE ARE TRUE AND THAT ALL STATEMENTS MADE ON INFORMATION AND BELIEF ARE BELIEVED TO BE TRUE; AND FURTHER THAT THESE STATEMENTS WERE MADE WITH THE KNOWLEDGE THAT WILLFUL FALSE STATEMENTS AND THE LIKE SO MADE ARE PUNISHABLE BY FINE OR IMPRISONMENT, OR BOTH, UNDER SECTION 1001 OF TITLE 18 OF THE UNITED STATES CODE AND THAT SUCH WILLFUL FALSE STATEMENTS MAY JEOPARDIZE THE VALIDITY OF THE APPLICATION OR ANY PATENT ISSUED THEREON.

10

Inventor's Full Name	<u>MAERTENS</u>	<u>GEERT</u>
Inventor's Signature		
Date:	<u>14 July 1997</u>	Country of Citizenship: <u>Belgium</u>
Residence Address	<u>Zilversparrenstraat 64</u> <u>B-8310 Brugge</u> <u>BEX</u> <u>BELGIUM</u>	
Post Office Address, if different from above	same as above	

2

Inventor's Full Name	<u>STUYVER</u>	<u>LIEVEN</u>
Inventor's Signature		
Date:	<u>April 11, 1997</u>	Country of Citizenship: <u>Belgium</u>
Residence Address	<u>Holestraat 8</u> <u>B-2400 Mol</u> <u>B-9552 Herzele</u> <u>BEX</u> <u>BELGIUM</u> 	
Post Office Address, if different from above	same as above	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GEERT MAERTENS ) Int'l App. No. PCT/EP95/04155  
and LIEVEN STUYVER )  
Serial No.: Unknown ) Group Art Unit: Unknown  
I.A. filing date: October 23, 1995 ) Examiner: Unknown  
For: NEW SEQUENCES OF HEPATITIS C ) Atty. Docket No.: INNS004/KAM  
VIRUS GENOTYPES AND THEIR USE AS )  
PROPHYLACTIC, THERAPEUTIC AND )  
DIAGNOSTIC AGENTS )

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: INNOGENETICS N.V.  
ADDRESS OF CONCERN: Industriepark, Zwijnaarde 7, Box 4  
B-9052 Gent, BELGIUM

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.


I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled **NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENTS** by inventors described in the specification filed as International Application No. PCT/EP95/04155.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I HEREBY DECLARE THAT ALL STATEMENTS MADE HEREIN OF MY OWN KNOWLEDGE ARE TRUE AND THAT ALL STATEMENTS MADE ON INFORMATION AND BELIEF ARE BELIEVED TO BE TRUE; AND FURTHER THAT THESE STATEMENTS WERE MADE WITH THE KNOWLEDGE THAT WILLFUL FALSE STATEMENTS AND THE LIKE SO MADE ARE PUNISHABLE BY FINE OR IMPRISONMENT, OR BOTH, UNDER SECTION 1001 OF TITLE 18 OF THE UNITED STATES CODE, AND THAT SUCH WILLFUL FALSE STATEMENTS MAY JEOPARDIZE THE VALIDITY OF THE APPLICATION, ANY PATENT ISSUING THEREON, OR ANY PATENT TO WHICH THIS VERIFIED STATEMENT IS DIRECTED.

Date: \_\_\_\_\_

SIGNATURE: \_\_\_\_\_

By:   
Dr. Hugo Van Heuverswyn  
Managing Director, INNOGENETICS N.V.  
Colmanstraat 62  
B-9270 Kalken, Belgium